What you should know:
1. Takeda wants to make 1.5 billion euros — $1.68 billion — from the sale.
2. The portfolio consists of over-the-counter and prescription medications where Takeda’s patent has expired. Despite that, the portfolio has an EBITDA of around 160 million euros ($179.6 million).
3. Takeda retained the services of JPMorgan to find a buyer.
4. Takeda’s acquisition of Shire put the company $52.73 billion in debt. To lower this, Takeda is attempting to sell $10 billion in assets.
More articles on surgery centers:
6 surgery centers achieving total joint milestones
Regent Surgical Health, Conformis partner to cut ASC joint replacement costs
ASC total joint program bundles, vendors & more — 3 insights from an administrator
